A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
Clinical trial NCT06280209 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06280209
- Sponsor
- BioMarin Pharmaceutical
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-03
- Primary completion
- 2027-04-14
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.